Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates (ADCs) represent a cutting-edge approach in targeted cancer therapy, ingeniously combining the precise targeting capabilities of monoclonal antibodies with the potent cell-killing effects of cytotoxic drugs. These sophisticated biopharmaceuticals are designed to specifically bind to antigens expressed on cancer cells. Upon binding, the ADC is internalized by the cancer cell, where the cytotoxic drug is released to induce cell death. This mechanism allows for direct delivery of the drug to the tumor, thereby enhancing efficacy while reducing the systemic toxicity associated with conventional chemotherapy. ADCs have shown significant promise in treating various cancers, offering a more personalized and effective treatment option.